MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.

IF 6.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reports Pub Date : 2026-08-01 DOI:10.1007/s11906-026-01380-9

Sainan Li, Michel Toutoungy, Janvi Patel, Indira Bhavsar-Burke, Lisa B VanWagner

{"title":"MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.","authors":"Sainan Li, Michel Toutoungy, Janvi Patel, Indira Bhavsar-Burke, Lisa B VanWagner","doi":"10.1007/s11906-026-01380-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disease. This review summarizes recent advances in epidemiology, pathophysiology, biomarkers, and treatment relevant to cardiovascular risk assessment and management.Recent findings: Fibrosis stage is the strongest independent predictor of cardiovascular outcomes in MASLD, conferring up to a 2.5-fold increase in events beyond traditional risk factors. Noninvasive tools, including Fibrosis-4 (FIB-4) and liver stiffness measurement, also predict cardiovascular mortality. Semaglutide and resmetirom offer dual hepatic and cardiometabolic benefits. MASLD affects 38% of adults globally, and cardiovascular disease (CVD) is the leading cause of death across disease stages. Fibrosis-based risk stratification remains absent from standard cardiovascular risk models despite its prognostic value. Therapies with combined liver and cardiovascular benefits are promising, but whether improving liver disease reduces cardiovascular events remains uncertain.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428797/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-026-01380-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disease. This review summarizes recent advances in epidemiology, pathophysiology, biomarkers, and treatment relevant to cardiovascular risk assessment and management.

Recent findings: Fibrosis stage is the strongest independent predictor of cardiovascular outcomes in MASLD, conferring up to a 2.5-fold increase in events beyond traditional risk factors. Noninvasive tools, including Fibrosis-4 (FIB-4) and liver stiffness measurement, also predict cardiovascular mortality. Semaglutide and resmetirom offer dual hepatic and cardiometabolic benefits. MASLD affects 38% of adults globally, and cardiovascular disease (CVD) is the leading cause of death across disease stages. Fibrosis-based risk stratification remains absent from standard cardiovascular risk models despite its prognostic value. Therapies with combined liver and cardiovascular benefits are promising, but whether improving liver disease reduces cardiovascular events remains uncertain.

查看原文本刊更多论文

MASLD和心血管风险：临床实践的机制和意义。

综述目的：代谢功能障碍相关脂肪变性肝病（MASLD）越来越被认为是一种全身性心脏代谢疾病。本文综述了与心血管风险评估和管理相关的流行病学、病理生理学、生物标志物和治疗方面的最新进展。最近的研究发现：纤维化阶段是MASLD心血管结局最强的独立预测因子，在传统危险因素之外，纤维化阶段的事件增加了2.5倍。无创工具，包括纤维化-4 （FIB-4）和肝脏硬度测量，也可以预测心血管死亡率。Semaglutide和resmerom提供肝脏和心脏代谢的双重益处。MASLD影响全球38%的成年人，心血管疾病（CVD）是各个疾病阶段的主要死亡原因。尽管具有预后价值，但在标准心血管风险模型中仍然缺乏基于纤维化的风险分层。肝脏和心血管联合治疗是有希望的，但改善肝脏疾病是否能减少心血管事件仍不确定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.